Literature DB >> 26166877

Synthesis of pyrrolo[3,2-a]phenazines from 5-nitroindoles and anilines.

Zbigniew Wróbel1, Michał Więcław2, Robert Bujok1, Krzysztof Wojciechowski1.   

Abstract

ABSTRACT: Anilines react with 5-nitroindoles in the presence of t-BuOK in N,N-dimethylformamide (DMF) to form 5-nitroso-4-arylaminoindoles that in turn when treated with N,O-bis(trimethylsilyl)acetamide cyclize to pyrrolo[3,2-a]phenazines. In an alternative approach pyrrolo[3,2-a]phenazines are formed from aminoindoles and nitroarenes.

Entities:  

Keywords:  Amines; Anions; Cyclizations; Heterocycles; Lewis acids; Nucleophilic substitutions

Year:  2013        PMID: 26166877      PMCID: PMC4495017          DOI: 10.1007/s00706-013-1087-3

Source DB:  PubMed          Journal:  Monatsh Chem        ISSN: 0026-9247            Impact factor:   1.451


Introduction

Phenazine derivatives are an important class of condensed heterocycles of natural origin [1-4]. Selected methods of synthesizing the phenazine framework are presented in Scheme 1. One of the oldest methods is the reaction of anilines with nitroarenes under basic conditions (the Wohl–Aue reaction, path a) [5]. The Holliman synthesis of phenazines (path b) is a base-induced cyclization of ortho-nitrodiphenylamines [6]. In the Bamberger–Ham reaction (path c) nitrosobenzenes dimerize under acidic conditions to form phenazines [7]. Other methods are the condensation of ortho-phenylenediamines with ortho-quinones (path d) [8], reaction of benzofuroxanes and phenols (the Beirut reaction, path e) [9], and palladium-catalyzed cyclization of 2-amino-2′-bromophenylenediamines (path f) [10].
The classic Wohl-Aue synthesis of phenazines consists in the reaction of anilines with nitroarenes under harsh basic conditions, usually by heating of both starting materials with sodium or potassium hydroxide at 200 °C [5]. In recent years we extensively studied nucleophilic aromatic substitution reactions of hydrogen in nitroarenes [11-15]. During these studies we have found that anilines react with nitrobenzene derivatives under mild conditions in the presence of t-BuOK in DMF at −50 °C to form 2-nitrosodiphenylamines that in turn upon treatment with acetic acid cyclized to phenazines (Scheme2) [16, 17].
Other transformations of 2-nitrosodiphenylamines into heterocyclic systems developed by us include reactions with benzyl aryl sulfones to form 1,2-diarylbenzimidazoles [18] and cyclocondensation with functionalized alkyl acetates, such as malonates, phenyl- and phosphonyl-acetates, leading to 1-arylquinoxalin-2(1H)-ones [16, 19]. 1,2-Benzo- and 1,2-heteroaryl-fused phenazines are of interest owing to their potential biological activity, as intercalators [20, 21], and antimicrobial agents [22, 23]. Reports on the synthesis of pyrrolo[3,2-a]phenazines are scarce. 1-(2-Aminoethyl)pyrrolo[3,2-a]phenazine was formed from 1,2-phenylenediamine and the 4,5-indoloquinone arising from electrochemical oxidation of 5-hydroxytryptamine [24]. Dipyrrolo[3,2-a:3,2-h]phenazines were synthesized in the oxidative dimerization of 5-aminoindoles [25]. Some pyrrolo[3,2-a]phenazine-10-carboxamides, obtained from 4-aminoindole and 2-iodo-3-nitrobenzoic acid, were tested as cytotoxic agents [26].

Results and discussion

In this paper we present a simple synthesis of pyrrolo[3,2-a]phenazines from nitroindoles and anilines. Thus when we treated 5-nitroindole derivatives 1 and anilines 2 with t-BuOK in DMF at −50 °C, the expected 4-(N-arylamino)-5-nitrosoindoles 3 were formed in good yields (Scheme 3 and Table 1).
Table 1

Synthesis of nitrosoindoles 3 and pyrrolo[3,2-a]phenazines 4

RXYield of 3/%Yield of 4/%
a MeCl6565
b CH2PhCl36a,b 88
c n-C8H17 CH3 3088
d n-C8H17 Cl5880
e n-C8H17 OCH3 5071
f n-C8H17 CF3 b 34

aYield of the crude product

bThe crude product without purification was subjected to cyclization to phenazine

Synthesis of nitrosoindoles 3 and pyrrolo[3,2-a]phenazines 4 aYield of the crude product bThe crude product without purification was subjected to cyclization to phenazine Some of these compounds (3b and 3f) proved unstable and thus after isolation without further purification they were used in the next step to form phenazines. The 1H and 13C NMR spectra of the obtained nitrosoamines 3 and 7 deserve some comments. In the spectra of some of these compounds we observed broadening of the signals corresponding to the protons and carbon atoms of the nitroso-substituted moiety and thus their full interpretation was troublesome. Such a signal broadening is probably due to a slow rotation of the nitroso group around the C–N bond. A similar phenomenon was observed in the NMR spectra of 2-(alkylamino)- and 2-(arylamino)nitrosobenzenes [27, 28]. In our earlier papers we have shown that cyclization of N-(2-nitrosophenyl)anilines to phenazines proceeds satisfactorily in boiling acetic acid [16, 17], with K2CO3 in methanol at room temperature [17], or with N,O-bis(trimethylsilyl)acetamide (BSA) [17]. Attempted cyclization of the model nitroso compound 3d in boiling acetic acid was unsuccessful; the starting material was consumed within 90 min (TLC control) but no defined products were obtained. No reaction of 3d was observed in the presence of K2CO3 in methanol. The cyclization of 3d occurs satisfactorily in the presence of BSA in DMF at 80 °C giving the expected pyrrolophenazine 4d in good yield. These reaction conditions were adapted to reactions of other 4-(N-arylamino)indoles 3. The results are summarized in the Table 1. Alternatively, the pyrrolo[2,3-a]phenazines can be obtained from aminoindoles and nitroarenes (Scheme 4). Thus, when we reacted 4-aminoindole 6a with 4-nitroanisole (5) under standard conditions (t-BuOK/DMF, −50 °C) the expected nitrosoaniline 7a was formed. Since the amine 7a proved unstable, it was without purification subjected to reaction with BSA and cyclized to 9-methoxypyrrolo[3,2-a]phenazine 4 g that was isolated in 90 % yield. Similarly 5-aminoindole 6b and 4-nitroanisole formed the relatively stable nitroso derivative 7b that was isolated in 40 % yield. Treatment of the compound 7b with BSA led to isomeric 8-methoxypyrrolo[3,2-a]phenazine 4 h in 64 % yield.
These reactions show the versatility of the proposed approach to pyrrolophenazines enabling the synthesis of derivatives bearing substituents in the desired position of the heterocyclic system, as exemplified by the synthesis of 8- and 9-methoxy derivatives 4 g and 4e that can be obtained from different nitroarene–amine pairs, namely 5-nitroindole and para-anisidine or 5-aminoindole (6b) and 4-nitroanisole (5). In summary, a novel two-step approach to pyrrolophenazines starting from easily available nitroindoles and anilines was developed. In an alternative reaction sequence the pyrrolophenazines can be obtained from nitroarenes and aminoindoles. The simplicity of this approach makes it an interesting alternative to other procedures.

Experimental

All reactions were performed under argon atmosphere. 1H and 13C NMR spectra were recorded on Bruker 500 MHz spectrometer (500 MHz for 1H and 125 MHz for 13C spectra). Chemical shifts (δ) are expressed in ppm referred to TMS, coupling constants in Hertz. Mass spectra (EI, 70 eV) were obtained on an AMD-604 spectrometer. ESI mass spectra were obtained on SYNAPT G2-S HDMS. Merck silica gel 60 F254 plates were used for TLC. Merck silica gel 60 (230–400 mesh) was used for flash column chromatography.

Typical procedure for synthesis of compoundsand

N-(4-Chlorophenyl)-1,2-dimethyl-5-nitroso-1H-indol-4-amine (3a, C16H14ClN3O)

4-Chloroaniline (0.32 g, 2.5 mmol) in 2 cm3 DMF was added to a solution of 0.67 g t-BuOK (6 mmol) in 10 cm3 DMF cooled to −50 °C. After 5 min a solution of 0.38 g 1,2-dimethyl-5-nitroindole (2 mmol) in 3 cm3 DMF was added. The reaction was stirred at −50 to −40 °C until the starting indole disappeared (1–2 h, TLC control, SiO2, toluene/ethyl acetate 10:1). Then the reaction mixture was poured into 100 cm3 water with 5 g NH4Cl. The precipitate was dissolved in 100 cm3 EtOAc and dried with Na2SO4. After evaporation of solvent the product was purified by column chromatography (SiO2, toluene/ethyl acetate). The product 3a was obtained as a dark red solid; m.p.: >285 °C (decomp.); R f = 0.18 (toluene/ethyl acetate 10:1); 1H NMR (500 MHz, CDCl3): δ = 2.21 (s, 3H), 3.61 (s, 3H), 5.41 (br s, 1H), 6.91 (br s, 1H), 7.15–7.26 (m, 2H), 7.37–7.38 (m, 2H), 8.14 (br s, 1H), 14.49 (s, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.47, 30.00, 104.55, 105.57, 111.77, 127.35, 128.18, 128.99, 129.33, 132.57, 134.94, 137.38, 141.32, 153.62 ppm; MS (ESI): m/z = 300 ([M + H]+, 100), 282 (8); HRMS (ESI): calcd. for C16H1535ClN3O 300.0904, found 300.0905.

1-Benzyl-N-(4-chlorophenyl)-2-methyl-5-nitroso-1H-indol-4-amine (3b, C22H18ClN3O)

Dark red unstable semisolid; MS (EI, 70 eV): m/z = 375 (M+, 42), 361 (55), 358 (38), 344 (12), 323 (33), 267 (9), 253 (32), 235 (36), 219 (19), 91 (100); HRMS (ESI): calcd. for C22H18ClN3NaO 398.1031, found 398.1040.

2-Methyl-N-(4-methylphenyl)-5-nitroso-1-octyl-1H-indol-4-amine (3c, C24H31N3O)

Dark red oil; R f = 0.32 (toluene/ethyl acetate 10:1); 1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.26–1.32 (m, 10H), 1.70 (m, 2H), 2.16 (s, 3H), 2.42 (s, 3H), 3.93 (t, J = 7.7 Hz, 2H), 6.60 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 7.13–7.28 (m, 3H), 14.69 (br s, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.43, 14.05, 22.59, 26.90, 29.12, 29.23, 30.47, 31.73, 31.78, 43.68, 104.56, 116.11, 111.92, 126.29, 129.24, 132.25, 133.76, 134.36, 135.78, 137.02, 140.54, 153.45 ppm; MS (ESI): m/z = 378 (M+, 100); HRMS (ESI): calcd. for C24H32N3O 378.2545, found 378.2548.

N-(4-Chlorophenyl)-2-methyl-5-nitroso-1-octyl-1H-indol-4-amine (3d, C23H28ClN3O)

Black solid; m.p.: 102–103 °C; R f = 0.40 (toluene/ethyl acetate 10:1); 1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 7.1 Hz, 3H), 1.27–1.33 (m, 10H), 1.70–1.73 (m, 2H), 2.20 (s, 3H), 3.96 (t, J = 7.5 Hz, 2H), 5.40 (br s, 1H), 6.91 (br s, 1H), 7.24–7.29 m, 2H), 7.34–7.42 (m, 2H), 8.13 (br s, 1H), 14.54 (s, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.44, 14.02, 22.55, 26.86, 29.09, 29.19, 30.43, 31.70, 43.76, 104.95, 105.90, 121.14, 127.41, 128.91, 129.38, 132.29, 133.12, 134.46, 137.34, 140.80, 153.35 ppm; MS (ESI, MeOH): m/z = 398 ([M + H]+, 100), 380 (10); HRMS (ESI): calcd. for C23H2935ClN3O 398.1999, found 398.1997.

N-(4-Methoxyphenyl)-2-methyl-5-nitroso-1-octyl-1H-indol-4-amine (3e, C24H31N3O2)

Black solid; m.p.: 77–79 °C; R f = 0.24 (toluene/ethyl acetate 10:1); 1H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 7.1 Hz, 3H), 1.26–1.32 (m, 10H), 1.67–1.71 (m, 2H), 2.16 (s, 3H), 3.87 (s, 3H), 3.94 (t, J = 7.8, 2H), 5.27 (s, 1H), 6.85 (d, J = 9.2 Hz, 1H), 6.94 (d, J = 8.7 Hz, 2H), 7.20 (d, J = 8.7 Hz, 2H), 8.06 (d, J = 9.2 Hz, 1H), 14.63 (s, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.39, 14.03, 22.56, 26.87, 29.10, 29.20, 30.44, 31.71, 43.67, 55.50, 104.53, 106.00, 111.83, 114.42, 127.81, 131.10, 132.15, 133.77, 135.00, 140.50, 153.28, 158.66 ppm; MS (ESI, MeOH): m/z = 394 (M+, 100); HRMS (EI): calcd. for C24H32N3O2 394.2495, found 394.2494.

1-Benzyl-N-(5-methoxy-2-nitrosophenyl)-2-methyl-1H-indol-4-amine (7a, C23H21N3O2)

Dark red crystals; m.p.: >115 °C (decomp); R f = 0.48 (toluene/ethyl acetate 10:1); 1H NMR (500 MHz, DMSO-d 6): δ = 2.38 (s, 3H), 3.75 (s, 3H), 5.46 (s, 2H), 6.23 (s, 1H), 6.43 (br s, 1H), 6.68 (br s, 1H), 6.90–7.04 (m, 2H), 7.12 (dd, J = 8.0, 7.6 Hz, 1H), 7.18 (d, J = 7.6 Hz, 1H), 7.21–7.25 (m, 1H), 7.27–7.32 (m, 2H), 7.36 (d, J = 8.0 Hz, 1H), 8.53 (br s, 1H), 13.21 (br s, 1H) ppm; 13C NMR (125 MHz, DMSO-d 6): δ = 46.48, 56.43, 60.20, 95.30, 98.02, 108.86, 109.98, 115.01, 121.44, 123.99, 126.57, 127.62, 129.11, 138.40, 138.55 ppm (spectrum not fully legible); MS (ESI, MeOH): m/z = 394 ([M + Na]+), 372 ([M + H]+); HRMS (ESI, [M + 1]+): calcd. for C23H22N3O2 372.1707, found 372.1718.

1-Benzyl-N-(5-methoxy-2-nitrosophenyl)-2-methyl-1H-indol-5-amine (7b, C23H21N3O2)

Dark brown crystals; yield 40 %; m.p.: >90 °C (decomp); R f = 0.38 (toluene/ethyl acetate 10:1); 1H NMR (500 MHz, DMSO-d 6): δ = 2.37 (s, 3H), 3.73 (s, 3H), 5.44 (s, 2H), 6.34 (s, 1H), 6.40 (br s, 1H), 6.64 (br s, 1H), 7.00–7.10 (m, 3H), 7.21–7.27 (m, 1H), 7.28–7.35 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.50 (br s, 1H), 12.98 (br s, 1H) ppm; 13C NMR (125 MHz, DMSO-d 6): δ = 12.49, 45.87, 55.88, 93.82, 100.39, 109.09, 110.51, 115.62, 117.91, 122.85, 125.85, 126.17, 127.13, 128.19, 128.63, 135.25, 138.17, 138.46, 142.05, 153.48, 166.67 ppm; MS (ESI, MeOH): m/z = 394 ([M + Na]+), 372 ([M + H]+); HRMS (ESI, [M + 1]+): calcd. for C23H22N3O2 372.1707, found 372.1713.

Typical procedure for synthesis of compounds

8-Chloro-2,3-dimethylpyrrolo[3,2-a]phenazine (4a, C16H12ClN3)

To 200 mg 4-arylamino-5-nitrosoindole 3 (0.66 mmol) dissolved in 10 cm3 DMF was added 0.67 g N,O-bis(trimethylsilyl)acetamide (3.3 mmol). The reaction mixture was stirred at 80 °C for 12–24 h (TLC control, n-hexane/ethyl acetate 4:1). Then the reaction mixture was poured into 100 cm3 water. The product was separated, dissolved in 50 cm3 EtOAc, and dried with Na2SO4. After evaporation of the solvent the product was purified by column chromatography (SiO2, n-hexane/ethyl acetate 4:1). Product 4a was obtained in the form of orange crystals; m.p.: >300 °C; R f = 0.22 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, DMF-d 7): δ = 2.59 (s, 3H), 3.96 (s, 3H), 7.18 (s, 1H), 7.76 (d, J = 9.4 Hz, 1H), 7.85 (dd, J = 9.0, 2.25 Hz, 1H), 8.18 (d, J = 9.4 Hz, 1H), 8.24–8.26 (m, 2H) ppm; 13C NMR (125 MHz, DMF-d 7): δ = 12.33, 27.56, 102.93, 120.37, 121.59, 122.54, 128.28, 130.63, 131.22, 133.70, 135.48, 137.46, 140.45, 140.98, 141.86, 143.19 ppm; MS (EI, 70 eV): m/z = 281 (M+, 100), 266 (8); HRMS (EI): calcd. for C16H12ClN3 281.0720, found 281.0717.

3-Benzyl-8-chloro-2-methylpyrrolo[3,2-a]phenazine (4b, C22H16ClN3)

Yellow crystals; m.p.: 223–225 °C; R f = 0.37 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, CDCl3): δ = 2.50 (d, J = 0.8 Hz, 3H), 5.48 (s, 2H), 6.9–7.00 (m, 2H), 7.26–7.32 (m, 3H), 7.73 (dd, J = 9.1, 2.3 Hz, 1H), 7.77 (d, J = 9.3 Hz, 1H), 7.79 (d, J = 9.3 Hz, 1H), 8.23 (d, J = 2.3 Hz, 1H), 8.26 (d, J = 9.2 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.86, 42.14, 103.48, 118.98, 122.00, 122.26, 125.83, 127.74, 127.87, 129.02, 130.22, 130.58, 134.09, 134.58, 136.09, 136.91, 139.71, 140.39, 141.38, 142.48 ppm; MS (ESI): m/z = 358 ([M + H]+); HRMS (ESI): calcd. for C22H17ClN3 358.1111, found 358.1113.

2,8-Dimethyl-3-octylpyrrolo[3,2-a]phenazine (4c, C24H29N3)

Brown–red solid; m.p.: 133–135 °C; R f = 0.54 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, CDCl3): δ = 0.87 (br s, 3H), 1.15–1.45 (m, 10H), 1.82 (m, 2H), 2.54 (s, 3H), 2.64 (s, 3H), 4.18 (m, 2H), 7.26 (s, 1H), 7.63 (br d, J = 8.0 Hz, 1H), 7.75–7.87 (m, 2H), 7.95–8.07 (m, 1H), 8.21 (br d, J = 8.0 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.84, 14.01, 21.99, 22.56, 26.96, 29.13, 29.26, 30.97, 31.71, 43.88, 102.79, 118.16, 121.41, 122.00, 127.54, 128.38, 132.19, 133.81, 135.17, 138.76, 139.23, 140.52, 141.27, 141.77 ppm; MS (EI, 70 eV): m/z = 359 (M+, 100), 344 (7), 316 (5), 288 (8), 274 (6), 260 (47), 246 (27), 233 (99); HRMS (EI): calcd. for C24H29N3 359.2361, found 359.2357.

8-Chloro-2-methyl-3-octylpyrrolo[3,2-a]phenazine (4d, C23H26ClN3)

Yellow crystals; m.p.: 157–159 °C; R f = 0.70 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, CDCl3): δ = 0.86 (t, J = 7.1 Hz, 3H), 1.26–1.40 (m, 10H), 1.79–1.85 (m, 2H), 2.55 (s, 3H), 4.19 (t, J = 7.6 Hz, 2H), 7.25 (s, 1H), 7.71 (dd, J = 9.1, 2.2 Hz, 1H), 7.78 (d, J = 9.3 Hz, 1H), 7.84 (d, J = 9.3 Hz, 1H), 8.23–8.25 (m, 2H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.84, 14.01, 22.56, 26.95, 29.12, 29.25, 30.98, 31.71, 43.95, 103.11, 119.05, 121.41, 121.88, 127.79, 130.10, 130.46, 133.94, 134.06, 135.54, 139.66, 140.16, 141.20, 142.39 ppm; MS (EI, 70 eV): m/z = 379 (M+, 100), 282 (19), 281 (15), 266 (23); HRMS (EI): calcd. for C23H2635ClN3 379.1815, found 379.1818.

8-Methoxy-2-methyl-3-octylpyrrolo[3,2-a]phenazine (4e, C24H29N3O)

Yellow crystals; m.p.: 122–124 °C; R f = 0.38 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, CDCl3): δ = 0.86 (t, J = 7.1 Hz, 3H), 1.25–1.39 (m, 10H), 1.81 (m, 2H), 2.56 (s, 3H), 4.01 (s, 3H), 4.19 (t, J = 7.6 Hz, 2H), 7.22 (s, 1H), 7.46–7.47 (m, 2H), 7.77 (d, J = 9.2 Hz, 1H), 7.81 (d, J = 9.2 Hz, 1H), 8.16 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.86, 14.02, 22.56, 26.96, 29.13, 29.27, 30.95, 31.71, 43.83, 55.70, 102.25, 105.11, 117.89, 120.99, 122.43, 124.19, 130.07, 133.44, 135.15, 138.29, 138.89, 141.66, 142.74, 159.68 ppm; MS (EI, 70 eV): m/z = 375 (M+, 100), 276 (21), 262 (12), 233 (20), 219 (10); HRMS (EI): calcd. for C24H29N3O 375.2311, found 375.2325.

2-Methyl-3-octyl-8-(trifluoromethyl)pyrrolo[3,2-a]phenazine (4f, C24H26F3N3)

Orange crystals; m.p.: 127–129 °C; R f = 0.74 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, CDCl3): δ = 0.87 (t, J = 7.1 Hz, 3H), 1.26–1.40 (m, 10H), 1.84 (m, 2H), 2.57 (s, 3H), 4.22 (t, J = 7.6 Hz, 2H), 7.29 (s, 1H), 7.82 (d, J = 9.3 Hz, 1H), 7.88 (d, J = 9.3 Hz, 1H), 7.93 (dd, J = 9.0, 2.0 Hz, 1H), 8.41 (d, J = 9.0 Hz, 1H), 8.58 (s, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.87, 14.03, 22.57, 26.96, 29.13, 29.26, 31.02, 31.72, 44.03, 103.46, 119.40, 121.70, 121.75, 124.02 (q, J = 272 Hz), 124.49, 127.67 (q, J = 4.9 Hz), 129.61 (q, J = 32 Hz), 130.18, 134.47, 135.72, 139.79, 140.77, 142.42, 143.05 ppm; MS (EI, 70 eV): m/z = 413 (M+, 100), 315 (45), 301 (11), 300 (23), 287 (9); HRMS (EI): calcd. for C24H26F3N3 413.2079, found 413.2090.

3-Benzyl-9-methoxy-2-methylpyrrolo[3,2-a]phenazine (4g, C23H19N3O)

Yield 90 %; orange crystals; m.p.: >250 °C; R f = 0.18 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, DMSO-d 6): δ = 2.48 (s, 3H), 4.03 (s, 3H), 5.65 (s, 2H), 7.04–7.08 (m, 2H), 7.18 (s, 1H), 7.23–7.35 (m, 3H), 7.52 (dd, J = 9.3, 2.5 Hz, 1H), 7.57 (d, J = 2.5 Hz, 1H), 7.72 (d, J = 9.0 Hz, 1H), 8.08 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 9.0 Hz, 1H) ppm; 13C NMR (125 MHz, DMSO-d 6): δ = 13.05, 46.82, 56.37, 102.99, 105.45, 118.18, 121.75, 121.94, 123.76, 126.66, 127.77, 129.22, 130.80, 135.02, 136.36, 138.05, 138.43, 139.43, 140.03, 143.53, 160.72 ppm; MS (ESI): m/z = 354 ([M + H]+); HRMS (ESI): calcd. for C23H20N3O 354.1601, found 354.1615.

3-Benzyl-8-methoxy-2-methylpyrrolo[3,2-a]phenazine (4h, C23H19N3O)

Yield 64 %; yellow crystals; m.p.: 225–227 °C; R f = 0.22 (n-hexane/ethyl acetate 4:1); 1H NMR (500 MHz, CDCl3): δ = 2.48 (d, J = 0.7 Hz, 3H), 4.01 (s, 3H), 5.45 (s, 2H), 6.97 (br s, 1H), 7.22–7.30 (m, 3H), 7.32 (s, 1H), 7.45–7.50 (m, 2H), 7.73 (d, J = 9.3 Hz, 1H), 7.75 (d, J = 9.3 Hz, 1H), 8.18 (d, J = 9.0 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 12.83, 47.00, 55.73, 102.75, 105.06, 117.86, 121.47, 122.73, 124.38, 125.83, 127.59, 128.93, 130.09, 133.98, 135.72, 137.17, 138.20, 138.98, 141.65, 142.82, 159.08 ppm; MS (ESI): m/z = 354 ([M + H]+); HRMS (ESI): calcd. for C23H20N3O 354.1601, found 354.1604.
  11 in total

1.  Nucleophilic substitution of hydrogen in heterocyclic chemistry.

Authors:  Mieczysław Makosza; Krzysztof Wojciechowski
Journal:  Chem Rev       Date:  2004-05       Impact factor: 60.622

Review 2.  Phenazine natural products: biosynthesis, synthetic analogues, and biological activity.

Authors:  Jane Buus Laursen; John Nielsen
Journal:  Chem Rev       Date:  2004-03       Impact factor: 60.622

3.  Tautomerization of 2-nitroso-N-arylanilines by coordination as N,N'-chelate ligands to rhenium(I) complexes and the anticancer activity of newly synthesized oximine rhenium(I) complexes against human melanoma and leukemia cells in vitro.

Authors:  Stefan Wirth; Andreas U Wallek; Anna Zernickel; Florian Feil; M Sztiller-Sikorska; K Lesiak-Mieczkowska; Christoph Bräuchle; Ingo-Peter Lorenz; M Czyz
Journal:  J Inorg Biochem       Date:  2010-04-01       Impact factor: 4.155

4.  Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.

Authors:  Nigel Vicker; Luke Burgess; Irina S Chuckowree; Rory Dodd; Adrian J Folkes; David J Hardick; Timothy C Hancox; Warren Miller; John Milton; Sukhjit Sohal; Shouming Wang; Stephen P Wren; Peter A Charlton; Wendy Dangerfield; Chris Liddle; Prakash Mistry; Alistair J Stewart; William A Denny
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

5.  Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents.

Authors:  Swarna A Gamage; Julie A Spicer; Gordon W Rewcastle; John Milton; Sukhjit Sohal; Wendy Dangerfield; Prakash Mistry; Nigel Vicker; Peter A Charlton; William A Denny
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

Review 6.  Of two make one: the biosynthesis of phenazines.

Authors:  Matthias Mentel; Ekta G Ahuja; Dmitri V Mavrodi; Rolf Breinbauer; Linda S Thomashow; Wulf Blankenfeldt
Journal:  Chembiochem       Date:  2009-09-21       Impact factor: 3.164

Review 7.  Phenazine compounds in fluorescent Pseudomonas spp. biosynthesis and regulation.

Authors:  Dmitri V Mavrodi; Wulf Blankenfeldt; Linda S Thomashow
Journal:  Annu Rev Phytopathol       Date:  2006       Impact factor: 13.078

8.  A new class of phenazines with activity against a chloroquine resistant Plasmodium falciparum strain and antimicrobial activity.

Authors:  Hidayat Hussain; Sabine Specht; Salem R Sarite; Michael Saeftel; Achim Hoerauf; Barbara Schulz; Karsten Krohn
Journal:  J Med Chem       Date:  2011-06-08       Impact factor: 7.446

Review 9.  Phenazines and cancer.

Authors:  A Cimmino; A Evidente; V Mathieu; A Andolfi; F Lefranc; A Kornienko; R Kiss
Journal:  Nat Prod Rep       Date:  2012-02-15       Impact factor: 13.423

10.  Mutational analysis of a phenazine biosynthetic gene cluster in Streptomyces anulatus 9663.

Authors:  Orwah Saleh; Katrin Flinspach; Lucia Westrich; Andreas Kulik; Bertolt Gust; Hans-Peter Fiedler; Lutz Heide
Journal:  Beilstein J Org Chem       Date:  2012-04-04       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.